1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Renal Pelvis Neoplasms: new trials by email Literature Review of Renal Pelvis Neoplasms trials Research Report on Renal Pelvis Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer enfortumab vedotin (EV), pembrolizumab, cisplatin - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 1 / Phase 2 | Terminated | Astellas Pharma Global Development, Inc. | 348 | 2017-10-11 | 2026-03-24 |
| A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Enfortumab vedotin - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 2 | Completed | Astellas Pharma Inc | 219 | 2017-10-08 | 2024-08-27 |
Carcinoma, Transitional Cell (2) · Ureteral Neoplasms (2) · Urethral Neoplasms (2) · Urinary Bladder Neoplasms (2) · Urologic Neoplasms (2)
Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Ureteral Diseases (2) · Urethral Diseases (2) · Urinary Bladder Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2)
enfortumab vedotin (2) · Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · pembrolizumab (1)
Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1)
France (2) · Italy (2) · Spain (2) · United States (2) · Canada (1) · Germany (1) · Japan (1) · Netherlands (1) · Puerto Rico (1) · South Korea (1)
Changting Meng, MD (1) · Janet Trowbridge, MD, PhD (1) · Jason Lukas, MD, PhD (1)
PMID 31356140, PMID 33991512, PMID 35168844, PMID 36041086, PMID 37369081, PMID 38215355